antirheumatics/vomiting

Lyen an sove nan clipboard la

AtikEsè klinikPatant

Chwazi kalite sòt

Paj 1 soti nan 31 rezilta yo

Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND It has been reported that antibodies to oral anaerobic bacteria are elevated in the serum and synovial fluids of patients with rheumatoid arthritis. Macrolide antibiotics are active against oral anaerobic bacteria. OBJECTIVE The aim of this work was to evaluate the clinical efficacy of

Granisetron (Kytril) suppresses methotrexate-induced nausea and vomiting among patients with inflammatory arthritis and is superior to prochlorperazine (Stemetil).

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Methotrexate (MTX) is an increasingly popular anti-rheumatic drug with its usefulness limited by toxicity, most commonly gastrointestinal (GI). The aim of the study was to study the effectiveness of the 5-HT3 receptor antagonist granisetron (GR) in the therapy of MTX-induced

Frequency of methotrexate intolerance in rheumatoid arthritis patients using methotrexate intolerance severity score (MISS questionnaire).

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The objective of the study was to determine the frequency of methotrexate intolerance in rheumatoid arthritis (RA) patients by applying the methotrexate intolerance severity score (MISS) questionnaire and to see the effect of dose and concomitant use of other disease-modifying antirheumatic drugs

Low-dose Methotrexate Toxicity in the Setting of Vancomycin-induced Acute Kidney Injury

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Methotrexate is a disease-modifying anti rheumatic drug (DMARD) that is often used in low dosages as the first line drug for rheumatoid arthritis patients. The chemotherapeutic agent works by inhibiting dihydrofolate reductase, and the primary route of clearance of the drug is via the kidneys.

[Treatment with low-dose methotrexate in chronic polyarthritis. Review of the literature].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

The therapeutic effect of low-dose MTX-treatment (10-25 mg/week) in active rheumatoid arthritis can be demonstrated by an improvement in clinical and laboratory parameters of disease activity already after 4-6 weeks. The mode of action is not fully understood. Direct anti-inflammatory effects seem

[Methotrexate in the therapy of juvenile idiopathic arthritis].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Treatment with low-dose methotrexate (MTX) is an important element in the therapy of juvenile idiopathic arthritis (JIA). It could be demonstrated in placebo-controlled trials that MTX is a safe and effective drug which is generally well tolerated by children and adolescents. MTX is usually used at

Apremilast (Otezla). No progress in plaque psoriasis or psoriatic arthritis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

When PUVA therapy and immunosuppressants such as methotrexate are ineffective, TNF alpha antagonists are an option for patients with severe plaque psoriasis, in the absence of a better alternative. This is also the case for patients with psoriatic arthritis after failure of a "disease-modifying"

A case of urinary incontinence by hydroxychloroquine in a geriatric patient.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Rheumatoid arthritis is an autoimmune disorder characterized by persistent synovitis and systemic inflammation. Genetic factors account for approximately 50% of cases of rheumatoid arthritis and environmental factors include smoking. Urinary incontinence may occur as a medication adverse

Methotrexate in rheumatoid arthritis: a 2 year experience at a university hospital in Pakistan.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

In this study we report our two years experience of methotrexate (MTX) in the management of rheumatoid arthritis (RA) at the Aga Khan University Hospital, Karachi. We studied the clinical course of 124 RA patients. The mean age was 44 +/- 11 years (range 19-72) and mean duration of RA was 5 +/- 4

[Gastrointestinal side effects in the therapy of rheumatologic diseases].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Antirheumatic drugs may lead to a number of relevant gastrointestinal complications. Symptomatical treatments with glucocorticoids and non steroidal antirheumatic drugs (NSAD) are known to induce gastric or duodenal ulcers, above all under combination therapies. Side effects of DMARD's

Efficacy and safety of DMARDs in psoriatic arthritis: a systematic review.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Disease-modifying antirheumatic drugs (DMARDs) are frequently prescribed as a first step therapy in active psoriatic arthritis (PsA). However, evidence is sparse and scattered. The objective of this study is to evaluate the efficacy and safety of DMARDs in PsA. METHODS We performed a

Is thiopurine methyltransferase genetic polymorphism a major factor for withdrawal of azathioprine in rheumatoid arthritis patients?

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To determine whether the presence of thiopurine methyltransferase (TPMT) alleles associated with reduced or absent activity of thiopurine methyltransferase is a major factor for withdrawal of azathioprine (AZA) in rheumatoid arthritis (RA) patients. METHODS The TPMT genotype, including the

Long-term therapy with tolfenamic acid pINN. A clinical and toxicological study with special reference to clinical and chemical laboratory parameters.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

48 patients with rheumatic diseases underwent long-term treatment with a new antirheumatic compound, tolfenamic acid pINN. The dosage was 2 capsules of 100 mg 3 times daily. At the time of summing-up 9 patients had been treated for one year, 41 for 6 months and 7 had been eliminated after 1 month of

Cyclophosphamide for rheumatoid arthritis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To estimate the short-term effects of cyclophosphamide for the treatment of rheumatoid arthritis. METHODS We searched the Cochrane Musculoskeletal Group's Register, the Cochrane Controlled Trials Register, Medline and Embase up to and including July 1997. We also carried out a handsearch

Cyclophosphamide for treating rheumatoid arthritis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE To assess the short-term effects of cyclophosphamide for the treatment of rheumatoid arthritis. METHODS We searched the Cochrane Musculoskeletal Group's Register, the Cochrane Controlled Trials Register (issue 3, 2000), Medline and Embase up to and including August 2000. We also carried

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye